Comparative Pharmacology
Head-to-head clinical analysis: KENGREAL versus ZONTIVITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENGREAL versus ZONTIVITY.
KENGREAL vs ZONTIVITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cangrelor is a reversible, direct-acting P2Y12 platelet receptor antagonist that inhibits ADP-mediated platelet activation and aggregation.
ZONTIVITY (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist that inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. It does not directly inhibit thrombin activity but blocks thrombin-mediated platelet activation.
10 mcg/kg intravenous bolus over 1-2 minutes, followed by 0.1 mcg/kg/min continuous intravenous infusion for 2-4 hours.
1 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 3–6 minutes (mean 3.3 minutes), allowing rapid recovery of platelet function within 60 minutes of infusion cessation.
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment.
Cangrelor is metabolized via rapid dephosphorylation to its major metabolite, a nucleoside, which is further degraded; approximately 58% of the dose is excreted in urine as unchanged cangrelor and metabolites, with <35% in feces.
Primarily as unchanged drug via renal excretion (approximately 80%) and fecal/biliary elimination (approximately 20%).
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent